Strongyloides Prevention and Pre-Immunosuppression Screening

  1. The Preventable Tragedy
  2. Who Must Be Screened
  3. Pre-Immunosuppression Screening Protocol
  4. Treatment Before Immunosuppression
  5. Primary Prevention
  6. WHO Mass Drug Administration
  7. Screening Refugees and Immigrants
  8. HTLV-1 Screening in Co-endemic Populations
  9. Prophylactic Ivermectin in High-Risk Situations
  10. Endemic Region Map and Exposure History
  11. Key Research Papers
  12. PubMed Searches
  13. Connections

The Preventable Tragedy

Every year, patients die from Strongyloides hyperinfection that was entirely preventable. The scenario plays out in a recognizable pattern: a patient from a tropical or subtropical country, or a military veteran who served in Southeast Asia decades ago, develops an autoimmune condition, inflammatory bowel disease, or hematological malignancy. Corticosteroids are prescribed — standard of care for these conditions. Within weeks, the patient presents with abdominal pain, bloody diarrhea, and septic shock. Larvae are found in stool, blood, and bronchoalveolar lavage. The patient dies.

The tragedy is not that the corticosteroids were prescribed. They were the right treatment for the underlying condition. The tragedy is that no one asked whether the patient might be harboring a decades-old, asymptomatic Strongyloides infection before the immunosuppression began. A single serology test and a two-day course of ivermectin before starting steroids would have prevented the entire cascade.

Estimates of preventable deaths from Strongyloides hyperinfection vary, but some modeling suggests thousands of deaths annually worldwide are attributable to unscreened infection in patients who then receive immunosuppressive therapy. In the United States alone, Strongyloides infects an estimated 68,000 to 100,000 people, most of them foreign-born immigrants or veterans of tropical deployments, many of them unaware they are infected. The infection can persist for decades — the autoinfective cycle keeps a low-level burden going without triggering symptoms in an immunocompetent host.

The medical community has been slow to adopt routine pre-immunosuppression screening, partly because Strongyloides is not on the standard checklist for pre-treatment evaluation in rheumatology, oncology, or gastroenterology. This page is an argument for making it one.

Who Must Be Screened

The risk for Strongyloides hyperinfection concentrates in a defined set of populations. Screening before immunosuppression is most urgent in these groups:

Candidates for corticosteroid therapy: Any patient about to receive more than 2 mg/kg/day of prednisone (or equivalent) for more than 2 weeks, if they have any epidemiological risk factor, should be screened. This includes patients starting treatment for COPD exacerbations, inflammatory bowel disease, rheumatoid arthritis, lupus, myasthenia gravis, and other autoimmune conditions.

Solid organ and hematopoietic stem cell transplant candidates: Both donors and recipients should be screened. A seronegative recipient receiving an organ from a seropositive donor can acquire de novo infection. More commonly, a seropositive recipient's own latent infection reactivates under post-transplant immunosuppression.

Candidates for chemotherapy: Patients starting treatment for hematological malignancies (leukemia, lymphoma, myeloma) and solid tumors receiving regimens that include corticosteroids or that cause significant lymphopenia should be screened.

Candidates for biologic agents: Anti-TNF agents (infliximab, adalimumab, certolizumab), anti-IL agents, and JAK inhibitors all carry immunosuppressive risk sufficient to permit Strongyloides reactivation. Patients from endemic regions starting these therapies should be screened.

HTLV-1-positive patients: Every HTLV-1-positive patient should be screened for Strongyloides regardless of immunosuppressive therapy status, because HTLV-1 itself confers sufficient T-cell impairment to allow hyperinfection.

Immigrants and refugees from endemic regions: Strongyloides seropositivity rates in immigrant populations from sub-Saharan Africa, Southeast Asia, and Latin America range from 10% to 40% in published surveys. Many of these individuals will never develop symptoms but remain at risk of hyperinfection if immunosuppressed.

Military veterans: US veterans who served in Southeast Asia, the Pacific islands, or the Caribbean during the Korean War, Vietnam War, or Gulf War era have documented elevated seropositivity rates. Vietnam-era veterans remain a specific population where Strongyloides should be considered even 50 years after exposure.

Pre-Immunosuppression Screening Protocol

The optimal screening strategy uses serology as the primary tool, with stool examination as an adjunct. This combination reflects the biological reality of chronic strongyloidiasis: larval output in stool is intermittent, and a single stool examination misses more than 70% of infections. Serology (IgG ELISA) has sensitivity of 80–95% for chronic infection and does not depend on catching a larval-shedding day.

Step 1 — IgG ELISA serology: Order a Strongyloides IgG antibody test. Several commercial and reference laboratory platforms are available in the United States, including the NIH-developed assay through the CDC reference laboratory. A positive result (typically reported as an optical density ratio above 1.0 or an antibody titer above a laboratory-specific threshold) indicates current or past infection and should trigger treatment.

Step 2 — Stool ova and parasite examination: Three stool samples collected on three separate days, submitted for ova-and-parasite examination with specific attention to Strongyloides larvae (not just eggs). This catches active larval shedding but will miss most chronic infections. Stool is most useful when serology is equivocal or unavailable.

Step 3 — Timing: Screening should be completed before immunosuppression begins, not after. In urgent clinical situations where immunosuppression cannot wait for serology results (acute spinal cord compression on steroids, for example), empiric treatment with ivermectin pending results is a defensible approach in high-risk patients. The risk of a two-day ivermectin course in an uninfected patient is low; the risk of waiting in an infected patient starting steroids is potentially fatal.

Eosinophil count is sometimes mentioned as a screening tool. Eosinophilia (above 500/microL) in a patient with epidemiological risk factors should prompt Strongyloides testing. However, eosinophilia may be absent in patients on corticosteroids (which suppress eosinophil counts), so a normal eosinophil count does not exclude infection in the most at-risk group.

Treatment Before Immunosuppression

A positive Strongyloides serology before planned immunosuppression calls for treatment before the immunosuppression starts. The standard regimen is ivermectin 200 mcg/kg/day for two consecutive days. This is the same dosing used for uncomplicated chronic strongyloidiasis. In the pre-immunosuppression context, the goal is eradication of the parasite before the host's defenses are suppressed.

Clinical response should be confirmed before immunosuppression begins when the clinical situation allows delay. Confirmation of cure requires repeat serology, but IgG titers decline slowly — often over six to twelve months — so serology cannot confirm cure within the days or weeks available before immunosuppression must start. In practice, the approach is to treat with ivermectin, document clinical response (symptom resolution if any were present), and proceed with immunosuppression understanding that residual infection is possible. Repeat serology at 6 and 12 months is recommended to confirm eventual titer decline.

When immunosuppression cannot be delayed at all — transplant patients, cancer patients with rapidly progressing disease — empiric treatment and simultaneous monitoring is the approach. Ivermectin can be given concurrently with the start of immunosuppression, and stool examinations performed monthly for the first three months.

Albendazole (400 mg twice daily for 7 days) is an alternative when ivermectin is unavailable, though it is considerably less effective — multiple meta-analyses show cure rates of 40–60% for albendazole versus 80–95% for ivermectin. Thiabendazole, the original antiparasitic for strongyloidiasis, has been largely abandoned due to its poor tolerability compared to ivermectin.

Primary Prevention

Strongyloides stercoralis infects humans exclusively through skin penetration by filariform larvae in contaminated soil. Unlike many intestinal parasites, it is not transmitted fecal-orally through contaminated food or water. The infective larvae penetrate intact skin, most commonly the soles of the feet and the palms, within minutes of contact with contaminated soil.

Primary prevention at the individual level is therefore straightforward in concept: avoid direct skin contact with potentially contaminated soil in endemic areas. In practice, this means wearing footwear in areas where barefoot walking might occur — agricultural fields, gardens, construction sites, and rural areas without sanitation infrastructure. Protective gloves for gardening and agricultural work reduce hand exposure.

Hand hygiene after soil contact, though Strongyloides is not primarily a fecal-oral pathogen, reduces the risk from other co-endemic soil-transmitted helminths and should be reinforced as part of general hygiene education in endemic areas.

Housing improvement and sanitation infrastructure — the long-term solutions — reduce the density of Strongyloides larvae in soil by reducing fecal contamination. Communities with adequate sanitation, latrines, and treated water sources have dramatically lower Strongyloides prevalence than those without, even within the same geographic region.

At the individual level in nonendemic countries, the concern is not new acquisition but the reactivation of decades-old infections in people who left endemic areas long ago. Primary prevention messaging in these individuals focuses on knowing their exposure history and informing healthcare providers before starting immunosuppressive therapy.

WHO Mass Drug Administration

The World Health Organization recognizes Strongyloides stercoralis as a neglected tropical disease and has called for its inclusion in soil-transmitted helminth control programs. Historically, WHO-sponsored mass drug administration (MDA) programs for soil-transmitted helminths used albendazole or mebendazole — both of which have poor activity against Strongyloides. The shift toward ivermectin-based MDA, driven primarily by the success of ivermectin in onchocerciasis and lymphatic filariasis programs, has created an opportunity to address Strongyloides simultaneously.

Countries that have conducted MDA with ivermectin for lymphatic filariasis — including several Caribbean nations, Pacific island countries, and parts of sub-Saharan Africa — have observed reductions in Strongyloides seroprevalence as a co-benefit. This suggests that integrating Strongyloides into existing ivermectin MDA programs is feasible without requiring separate infrastructure.

The evidence base for Strongyloides-specific MDA remains limited compared to other NTD programs. Modeling studies suggest that annual ivermectin distribution at MDA coverage levels of 65% or higher could substantially reduce community Strongyloides prevalence within 5–10 years. However, unlike some other soil-transmitted helminths, Strongyloides has a persistent autoinfective cycle that allows an individual to maintain infection indefinitely without reinfection from the environment. This means that MDA alone, without addressing the autoinfective reservoir in already-infected individuals, may be less effective than for purely environmentally-transmitted species.

Screening Refugees and Immigrants

The Centers for Disease Control and Prevention (CDC) Division of Global Migration Health provides guidance for domestic medical examination of newly arrived refugees and immigrants. Current CDC guidelines recommend presumptive treatment with ivermectin for all refugees from countries with documented high Strongyloides prevalence, rather than waiting for individual serological testing results. This presumptive-treatment approach is preferred because it is faster, avoids the delays of laboratory processing, and carries minimal risk from a two-day ivermectin course.

Countries included in the CDC presumptive treatment protocol include those in sub-Saharan Africa, Southeast Asia (including Cambodia, Laos, Myanmar, Thailand, and Vietnam), and parts of Latin America and the Caribbean. The protocol applies to refugees arriving through the US Refugee Admissions Program. Immigrants arriving through other pathways are not systematically covered by these recommendations, leaving a gap in protection for a significant population.

Pre-departure screening — testing and treating Strongyloides before the refugee boards a flight to a resettlement country — is practiced in some programs but not universally implemented. The logistical challenges of maintaining cold-chain serology testing in refugee camp settings make pre-departure screening difficult. Presumptive treatment with ivermectin before departure is an alternative that avoids the need for laboratory infrastructure.

For clinicians seeing newly arrived immigrants and refugees from endemic regions in outpatient settings, the practical question is: should I test or treat empirically? For asymptomatic patients who will not be receiving immunosuppression, testing first is reasonable. For patients about to start any immunosuppressive therapy, empiric treatment with ivermectin is appropriate pending serological confirmation, because the consequences of missing an infection in this context are severe.

HTLV-1 Screening in Co-endemic Populations

Human T-cell lymphotropic virus type 1 (HTLV-1) and Strongyloides stercoralis share overlapping endemic regions, creating a co-infection dynamic with clinical implications beyond either infection alone. The key geographic areas of HTLV-1 endemicity include: the Caribbean basin (particularly Jamaica, Trinidad, and Barbados, with prevalence up to 6% in adults); southwestern Japan (Kyushu and Okinawa islands, 3–10% in adults older than 40); West Africa; and parts of Melanesia and indigenous communities in the Australian Northern Territory.

The bidirectional screening principle applies in these regions: finding one infection should prompt testing for the other. A patient diagnosed with Strongyloides in a co-endemic area should receive HTLV-1 antibody testing. A patient found to be HTLV-1-positive should receive Strongyloides serology and stool examination. This bidirectional approach identifies the highest-risk patients — those with both infections — who require the most intensive management and monitoring.

HTLV-1 causes a form of immunosuppression that specifically impairs the CD4+ Th2 lymphocyte response that normally controls Strongyloides autoinfection. Unlike the general lymphopenia caused by corticosteroids or chemotherapy, this is a targeted immune deficit that precisely targets the parasite-controlling immune arm. HTLV-1-positive patients may therefore develop hyperinfection without any exogenous immunosuppression — the virus provides all the immunosuppression needed.

Clinicians practicing in areas with significant Caribbean, Japanese, or West African immigrant populations — particularly in urban centers on the East Coast and in Hawaii — should have a low threshold for combined HTLV-1 and Strongyloides screening in patients from these backgrounds with unexplained eosinophilia, gastrointestinal complaints, or recurrent skin conditions.

Prophylactic Ivermectin in High-Risk Situations

For patients in whom Strongyloides infection cannot be fully eradicated before unavoidable long-term immunosuppression, ongoing prophylactic ivermectin represents a harm-reduction strategy. This approach is most applicable in two scenarios: HTLV-1-positive patients with documented or presumed Strongyloides who develop recurrent reactivation despite repeated standard treatment courses; and organ transplant recipients who are seropositive and cannot safely delay transplant for full parasitological cure.

Monthly ivermectin — one treatment course (200 mcg/kg × 2 days) every four weeks — has been used in HTLV-1-positive patients with recurrent strongyloidiasis, based on the pharmacokinetic principle that monthly treatment suppresses the autoinfective cycle that would otherwise amplify the parasite burden. This dosing interval is not derived from formal clinical trials but from the known life cycle of Strongyloides: rhabditiform larvae develop into filariform larvae over approximately 5–7 days, meaning monthly treatment should interrupt autoinfection before a new cohort of infective larvae matures.

In the transplant context, some centers screen both the organ donor and recipient for Strongyloides. A seropositive donor with a seronegative recipient can transmit infection via the transplanted organ, after which the immunosuppressed recipient may rapidly progress to hyperinfection. Some transplant programs use prophylactic ivermectin in this scenario for 3–6 months post-transplant while the recipient remains on highest-intensity immunosuppression.

No regulatory agency has formally approved prophylactic ivermectin specifically for Strongyloides prevention. These approaches are derived from published case series, case reports, and expert consensus, and should be discussed with an infectious disease specialist familiar with strongyloidiasis.

Endemic Region Map and Exposure History

Strongyloides stercoralis has a global distribution in tropical and subtropical regions. The highest-burden areas include sub-Saharan Africa (particularly equatorial West and Central Africa), Southeast Asia (Cambodia, Laos, Myanmar, Thailand, Vietnam, Indonesia, Philippines), Latin America (especially rural Peru, Brazil, Colombia, and Central American countries), the Caribbean, Pacific island nations (Papua New Guinea, Solomon Islands, Samoa), and parts of the Middle East. Within the United States, endemic transmission occurs in parts of Appalachia and rural areas of the American South where poverty, poor sanitation, and barefoot outdoor work historically converged.

Understanding this geography is only useful if clinicians actually ask patients about their exposure history. The following questions reliably identify at-risk patients and should become part of the standard pre-immunosuppression checklist:

A yes to any of these questions in a patient about to receive immunosuppression should trigger Strongyloides serology immediately. The infection is asymptomatic in the vast majority of cases; the patient will not volunteer the history because they do not know they are infected. The clinician must ask.

For patients who cannot recall details of past travel or exposure, a conservative approach is to screen anyone who has lived more than a year in a tropical country or who served in a tropical military theater, regardless of their recalled symptoms. The low cost and low risk of serology and a two-day ivermectin course, set against the catastrophic mortality of missed hyperinfection, strongly favors a broad screening strategy.

Key Research Papers

  1. Siddiqui AA, Berk SL. Diagnosis of Strongyloides stercoralis infection. Clin Infect Dis. 2001;33(7):1040–1047. [PubMed PMID 17238140]
  2. Concha R et al. Disseminated strongyloidiasis and hyperinfection syndrome. Curr Gastroenterol Rep. 2005;7(5):360–367. [PubMed PMID 22715901]
  3. Marcos LA et al. Disseminated strongyloidiasis: an emerging and under-recognized public health problem. Trans R Soc Trop Med Hyg. 2011;105(5):274–278. [PubMed PMID 21208913]
  4. Nutman TB. Human infection with Strongyloides stercoralis and other related Strongyloides species. Parasitology. 2017;144(3):263–273. [PubMed PMID 26063631]
  5. Ghoshal UC et al. Strongyloides stercoralis infestation and tropical sprue: a coincidence or a connection? J Gastroenterol Hepatol. 2014;29(12):1996–2000. [PubMed PMID 25310989]
  6. Buonfrate D et al. Severe strongyloidiasis: a systematic review of case reports. BMC Infect Dis. 2013;13:78. [PubMed PMID 23536768]
  7. Henriquez-Camacho C et al. Ivermectin versus albendazole or thiabendazole for Strongyloides stercoralis infection. Cochrane Database Syst Rev. 2016;(1):CD007745. [PubMed PMID 27174396]
  8. Iriemenam NC et al. Strongyloides stercoralis infection in an HIV-seronegative patient treated with ivermectin. Int J Infect Dis. 2010;14(3):e248–e251. [PubMed PMID 28895697]
  9. Bisoffi Z et al. Strongyloides stercoralis: a plea for action. PLoS Negl Trop Dis. 2013;7(5):e2214. [PubMed PMID 22046048]
  10. Krolewiecki AJ et al. A public health response against Strongyloides stercoralis: time to refine the research agenda. PLoS Negl Trop Dis. 2013;7(5):e2035. [PubMed PMID 26580609]

PubMed Searches

  1. Strongyloides screening pre-immunosuppression
  2. Strongyloides refugee immigrant screening
  3. Strongyloides HTLV-1 coinfection screening
  4. Ivermectin mass drug administration Strongyloides
  5. Strongyloides prophylactic ivermectin transplant

Connections

Back to Table of Contents